Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?

Expert Rev Hematol. 2013 Oct;6(5):485-7. doi: 10.1586/17474086.2013.827884. Epub 2013 Oct 2.

Authors

Vu H Duong¹, Eric Padron, Alan F List, Rami S Komrokji

Affiliation

¹ University of Maryland Greenebaum Cancer Center, Baltimore, 22 S. Greene Street, S9D04B, Baltimore, MD 21201, USA +1 410 328 2567 +1 410 328 6896 vduong@umm.edu.

PMID: 24083503
DOI: 10.1586/17474086.2013.827884

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents / therapeutic use*
Humans
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / enzymology*
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Protein-Tyrosine Kinases